Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. has announced a change in major holdings, with BlackRock, Inc. now holding 7.90% of voting rights, up from a previous 7.80%. This adjustment in BlackRock’s stake reflects a slight increase in their influence within the company, potentially impacting MaxCyte’s strategic decisions and signaling confidence from a major institutional investor.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell engineering and providing cell-based therapies. The company is known for its proprietary cell engineering platform that supports a wide range of applications, including drug discovery and development, biomanufacturing, and cell therapy.
Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue